Ovarian Cancer

Adoptive Immunotherapy Reported Safe and Feasible

Published in Women's Health Weekly, September 21st, 2000

Adoptive immunotherapy using anti-HER2/neu + anti-Fc gamma RI bispecific antibody in patients with ovarian cancer was safe and feasible, researchers in France and Belgium reported at a recent conference.

A. de Gramont and colleagues at Hospital St. Antoine and IDM, Paris, and Erasme Hospital, Brussels, conducted a study "to assess the safety and the efficacy of intraperitoneal (i.p.) injections of monocyte-derived activated killer cells (MAK) mixed with anti-HER2/neu + anti-Fc gamma RI bispecific antibody on the residual disease (RD) of ovarian cancer after surgery and chemotherapy."

They presented study data at the 36th Annual Meeting of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry